search
Back to results

Evaluating Use of Continuous Glucose Monitors in a Short-term 2x2-Crossover Study

Primary Purpose

Diabetes Type 2, Diabetes Mellitus

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
WB-011
Placebo
Continuous Glucose Monitor
Sponsored by
Pendulum Therapeutics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Type 2

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Age: 18 to 75 years of age
  • If female, must meet all the following criteria:
  • Not pregnant or breastfeeding
  • If of childbearing potential (including peri-menopausal women who have had a menstrual period within one year) must practice and be willing to continue to practice appropriate birth control (defined as a method which results in a low failure rate, i.e., less than 1% per year, when used consistently and correctly, such as double barrier methods [male condom with spermicide, with or without cervical cap or diaphragm], implants, injectable or oral contraceptives [must have been using for at least the last 3 months], some intrauterine contraceptive devices, tubal ligation, or in an established relationship with a vasectomized partner) during the entire duration of the study
  • Must be able to read, understand, and sign the informed consent forms (ICF) and, when applicable, an authorization to use and disclose protected health information form (consistent with Health Insurance Portability and Accountability Act of 1996 [HIPAA] legislation as modified in 2013)
  • Must be able to communicate with the investigator, and understand and comply with protocol requirements
  • Must be able to wear a CG patch and perform a scan no less than once every 8 hours for the duration of the sensor periods.

Exclusion Criteria:

  • Subjects who plan to use antibiotic, antifungal, antiparasitic, or antiviral treatment during the study
  • Subjects using a proton pump inhibitor must be on a stable dose that will be maintained throughout the study period
  • Subjects who plan to travel outside the United States during the projected study period
  • Subjects who have received an experimental drug within 30 days prior to study entry
  • Subjects with known milk, peanut, or tree nut allergies
  • Subjects who have been diagnosed with a sexually transmitted disease including, but not limited to, HIV, syphilis, herpes, gonorrhea, hepatitis A, hepatitis B, and hepatitis C
  • History of any surgery on the gastrointestinal tract except appendectomy and cholecystectomy
  • Subjects with any condition that the investigator deems as a sound reason for disqualification from enrollment into the study

Sites / Locations

  • Pendulum Therapeutics Inc

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

WB-011

Placebo

Arm Description

3 capsules administered twice daily with morning and evening meal for 2 weeks

3 capsules administered twice daily with morning and evening meal for 2 weeks

Outcomes

Primary Outcome Measures

Temperature as a Source of Unwanted Variation When Using Freestyle Libre Glucose Sensors
Temperature impacts the glucose level recorded by the Freestyle Libre glucose sensors. The thermostat of the Freestyle Libre glucose sensors can be assessed.
2-hour Interstitial Glucose Area Under the Curve (AUC)
Change in area under interstitial glucose concentration versus time curve (AUC) during standardized self-administered 2-hour Meal Tolerance Test.

Secondary Outcome Measures

Change in Body Mass
Weight measured via Scale
Change in Fecal Quantitative PCR Measures of Probiotic Strain Concentration
Fecal quantitative PCR of product strain will be measured throughout the study if subject provide stool samples. Mass Fraction is measured and the delta between the start and end of each period is computed.
Expected Lifespan of Continuous Glucose Monitoring (CGM) Sensors
To measure the lifespan of CGM sensors, we recorded how many sensors were worn per participant during the study. Sensors were replaced either at the end of the recommended 10-day period, or when they were accidentally removed.
Number of Pictures Per Day
Average number of pictures per day using the smartphone application per period, used to measure study fatigue.
Time Between CGM-sensor Scans
Average number of hours between CGM-sensor scans using the smartphone application during the study period. The subjects were instructed to scan at least every eight hours because the CGM-sensor does not save the data after eight hours without scanning.
CGM-Smartphone Usability Feedback
Questionnaire to assess usability of the CGM-sensor using the smartphone application. Question was: "Would you recommend others to a study like this? On a scale of 1-10 with 1 being no and 10 being absolutely"

Full Information

First Posted
May 27, 2020
Last Updated
November 10, 2022
Sponsor
Pendulum Therapeutics
search

1. Study Identification

Unique Protocol Identification Number
NCT04424888
Brief Title
Evaluating Use of Continuous Glucose Monitors in a Short-term 2x2-Crossover Study
Official Title
Evaluating Use of Continuous Glucose Monitors in a Short-term 2x2-Crossover Study
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Completed
Study Start Date
March 15, 2018 (Actual)
Primary Completion Date
April 29, 2018 (Actual)
Study Completion Date
June 29, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pendulum Therapeutics

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This 5-week, double-blind, placebo-controlled, 2x2 crossover pilot study investigate the potential of collecting robust, real-time clinical study measures of glucose levels using Abbott Freestyle Libre Continuous Glucose Monitoring devices associated with a smartphone application
Detailed Description
The goal of this study is to characterize the performance of a Continuous Glucose Monitoring System in medical food studies. The Freestyle Libre Glucose Sensors will be used to follow subject's 8-day glucose trajectories over the course of a 5-week, double-blind, placebo-controlled, 2x2 crossover, medical-food experiment. The medical food has been designed to increase butyrate production and promote the health of the colonic mucin layer.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Type 2, Diabetes Mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
6 (Actual)

8. Arms, Groups, and Interventions

Arm Title
WB-011
Arm Type
Experimental
Arm Description
3 capsules administered twice daily with morning and evening meal for 2 weeks
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
3 capsules administered twice daily with morning and evening meal for 2 weeks
Intervention Type
Other
Intervention Name(s)
WB-011
Intervention Description
WB-011 medical food product.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Placebo Capsules identical to those containing WB-011.
Intervention Type
Device
Intervention Name(s)
Continuous Glucose Monitor
Intervention Description
Abbott Freestyle Libre(™) Glucose Sensors were used throughout the study.
Primary Outcome Measure Information:
Title
Temperature as a Source of Unwanted Variation When Using Freestyle Libre Glucose Sensors
Description
Temperature impacts the glucose level recorded by the Freestyle Libre glucose sensors. The thermostat of the Freestyle Libre glucose sensors can be assessed.
Time Frame
Through study completion, an average of 5 weeks
Title
2-hour Interstitial Glucose Area Under the Curve (AUC)
Description
Change in area under interstitial glucose concentration versus time curve (AUC) during standardized self-administered 2-hour Meal Tolerance Test.
Time Frame
Change from baseline to 2 weeks
Secondary Outcome Measure Information:
Title
Change in Body Mass
Description
Weight measured via Scale
Time Frame
Change from baseline to 2 weeks
Title
Change in Fecal Quantitative PCR Measures of Probiotic Strain Concentration
Description
Fecal quantitative PCR of product strain will be measured throughout the study if subject provide stool samples. Mass Fraction is measured and the delta between the start and end of each period is computed.
Time Frame
Change from baseline to 2 weeks
Title
Expected Lifespan of Continuous Glucose Monitoring (CGM) Sensors
Description
To measure the lifespan of CGM sensors, we recorded how many sensors were worn per participant during the study. Sensors were replaced either at the end of the recommended 10-day period, or when they were accidentally removed.
Time Frame
Through study completion, an average of 5 weeks
Title
Number of Pictures Per Day
Description
Average number of pictures per day using the smartphone application per period, used to measure study fatigue.
Time Frame
2 weeks, (First intervention or second intervention)
Title
Time Between CGM-sensor Scans
Description
Average number of hours between CGM-sensor scans using the smartphone application during the study period. The subjects were instructed to scan at least every eight hours because the CGM-sensor does not save the data after eight hours without scanning.
Time Frame
2 weeks, (First intervention or second intervention)
Title
CGM-Smartphone Usability Feedback
Description
Questionnaire to assess usability of the CGM-sensor using the smartphone application. Question was: "Would you recommend others to a study like this? On a scale of 1-10 with 1 being no and 10 being absolutely"
Time Frame
Through study completion, an average of 5 weeks.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age: 18 to 75 years of age If female, must meet all the following criteria: Not pregnant or breastfeeding If of childbearing potential (including peri-menopausal women who have had a menstrual period within one year) must practice and be willing to continue to practice appropriate birth control (defined as a method which results in a low failure rate, i.e., less than 1% per year, when used consistently and correctly, such as double barrier methods [male condom with spermicide, with or without cervical cap or diaphragm], implants, injectable or oral contraceptives [must have been using for at least the last 3 months], some intrauterine contraceptive devices, tubal ligation, or in an established relationship with a vasectomized partner) during the entire duration of the study Must be able to read, understand, and sign the informed consent forms (ICF) and, when applicable, an authorization to use and disclose protected health information form (consistent with Health Insurance Portability and Accountability Act of 1996 [HIPAA] legislation as modified in 2013) Must be able to communicate with the investigator, and understand and comply with protocol requirements Must be able to wear a CG patch and perform a scan no less than once every 8 hours for the duration of the sensor periods. Exclusion Criteria: Subjects who plan to use antibiotic, antifungal, antiparasitic, or antiviral treatment during the study Subjects using a proton pump inhibitor must be on a stable dose that will be maintained throughout the study period Subjects who plan to travel outside the United States during the projected study period Subjects who have received an experimental drug within 30 days prior to study entry Subjects with known milk, peanut, or tree nut allergies Subjects who have been diagnosed with a sexually transmitted disease including, but not limited to, HIV, syphilis, herpes, gonorrhea, hepatitis A, hepatitis B, and hepatitis C History of any surgery on the gastrointestinal tract except appendectomy and cholecystectomy Subjects with any condition that the investigator deems as a sound reason for disqualification from enrollment into the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chief Technical Officer, PhD
Organizational Affiliation
Pendulum Therapeutics
Official's Role
Principal Investigator
Facility Information:
Facility Name
Pendulum Therapeutics Inc
City
San Francisco
State/Province
California
ZIP/Postal Code
94107
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33661120
Citation
Roux de Bezieux H, Bullard J, Kolterman O, Souza M, Perraudeau F. Medical Food Assessment Using a Smartphone App With Continuous Glucose Monitoring Sensors: Proof-of-Concept Study. JMIR Form Res. 2021 Mar 4;5(3):e20175. doi: 10.2196/20175.
Results Reference
derived

Learn more about this trial

Evaluating Use of Continuous Glucose Monitors in a Short-term 2x2-Crossover Study

We'll reach out to this number within 24 hrs